reported that treatment with daratumumab increases MM cell death, especially in the presence of a subset of CD14+/CD16+ monocytes, and that combining daratumumab with anti-CD47 enhances the elimination of MM cells that are resistant to daratumumab alone (66). Here, CD14 is linked to Miyoshi myopathy.